420 related articles for article (PubMed ID: 21050974)
1. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
[TBL] [Abstract][Full Text] [Related]
2. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
Gujral DM; Lloyd G; Bhattacharyya S
Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
[TBL] [Abstract][Full Text] [Related]
5. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?
Oliva S; Cioffi G; Frattini S; Simoncini EL; Faggiano P; Boccardi L; Pulignano G; Fioretti AM; Giotta F; Lestuzzi C; Maurea N; Sabatini S; Tarantini L;
Oncologist; 2012; 17(7):917-24. PubMed ID: 22673631
[TBL] [Abstract][Full Text] [Related]
6. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy.
Huang G; Zhai J; Huang X; Zheng D
Medicine (Baltimore); 2018 Sep; 97(38):e12447. PubMed ID: 30235730
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
Lynce F; Barac A; Geng X; Dang C; Yu AF; Smith KL; Gallagher C; Pohlmann PR; Nunes R; Herbolsheimer P; Warren R; Srichai MB; Hofmeyer M; Cunningham A; Timothee P; Asch FM; Shajahan-Haq A; Tan MT; Isaacs C; Swain SM
Breast Cancer Res Treat; 2019 Jun; 175(3):595-603. PubMed ID: 30852761
[TBL] [Abstract][Full Text] [Related]
9. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
Blanter JB; Frishman WH
Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
[TBL] [Abstract][Full Text] [Related]
10. [Cardioprotective treatment during adjuvant cancer therapy].
Gulati G; Heck SL; Ree AH; Gravdehaug B; Røsjø H; Steine K; Bratland Å; Hoffmann P; Geisler J; Omland T
Tidsskr Nor Laegeforen; 2013 Sep; 133(17):1832-6. PubMed ID: 24042297
[TBL] [Abstract][Full Text] [Related]
11. Ivabradine in Cancer Treatment-Related Left Ventricular Dysfunction.
Sarocchi M; Arboscello E; Ghigliotti G; Murialdo R; Bighin C; Gualandi F; Sicbaldi V; Balbi M; Brunelli C; Spallarossa P
Chemotherapy; 2018; 63(6):315-320. PubMed ID: 30840967
[TBL] [Abstract][Full Text] [Related]
12. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection.
Negishi K; Negishi T; Haluska BA; Hare JL; Plana JC; Marwick TH
Eur Heart J Cardiovasc Imaging; 2014 Mar; 15(3):324-31. PubMed ID: 24057661
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
[TBL] [Abstract][Full Text] [Related]
14. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
Gao Y; Wang R; Jiang J; Hu Y; Li H; Wang Y
Heart Fail Rev; 2023 Nov; 28(6):1405-1415. PubMed ID: 37414918
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study.
Hamirani Y; Fanous I; Kramer CM; Wong A; Salerno M; Dillon P
Med Oncol; 2016 Jul; 33(7):82. PubMed ID: 27334792
[TBL] [Abstract][Full Text] [Related]
16. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.
Kalam K; Marwick TH
Eur J Cancer; 2013 Sep; 49(13):2900-9. PubMed ID: 23706982
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
Yun S; Vincelette ND; Abraham I
Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
[TBL] [Abstract][Full Text] [Related]
18. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.
Barron CC; Alhussein MM; Kaur U; Cosman TL; Tyagi NK; Brown M; Mukherjee SD; Ellis PM; Dhesy-Thind S; Leong DP
Curr Oncol; 2019 Aug; 26(4):240-246. PubMed ID: 31548803
[TBL] [Abstract][Full Text] [Related]
20. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
